Christopher J. Sweeney, MBBS, presented “Update on the ARCHES Trial: New Indication for Enzalutamide in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)” for the Grand Rounds in Urology audience in December 2019.
How to cite: Sweeney, Christopher J. “Update on the ARCHES Trial: New Indication for Enzalutamide in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)” December, 2019. Accessed Dec 2024. https://dev.grandroundsinurology.com/update-on-the-arches-trial-new-indication-for-enzalutamide-in-metastatic-hormone-sensitive-prostate-cancer-mhspc/
Update on the ARCHES Trial: New Indication for Enzalutamide in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) – Summary:
Investigator Christopher J. Sweeney, MBBS, a medical oncologist at the Dana-Farber Cancer Institute and professor of medicine at Harvard, gives an overview of the trial (a companion to the ARCHES study), which demonstrated a survival benefit in all versions of mHSPC (metastatic hormone-sensitive prostate cancer) with the use of enzalutamide. Dr. Sweeney discusses how ENZAMET builds on the research conducted with ARCHES, the differences between enzalutamide and chemotherapy for high-burden, rapidly progressing disease, and why monotherapy should be phased out for PCa treatment in most patients.
ABOUT THE AUTHOR
Christopher J. Sweeney, MBBS, is a Medical Oncologist at the Dana-Farber Cancer Institute in Boston, Massachusetts, and Professor of Medicine at Harvard Medical School. He received his medical degree from the University of Adelaide in Australia, and then completed an internship at the Royal Adelaide Hospital. Dr. Sweeney did his residency in internal medicine at Gundersen Lutheran Medical Center in La Crosse, Wisconsin. He went on to complete a Fellowship in Hematology/Oncology at Indiana University Medical Center in Indianapolis, where he was later appointed Associate Director for Clinical Research for the Simon Cancer Center. Dr. Sweeney joined the Lank Center for Genitourinary Oncology at DFCI and Harvard Medical School in 2009. His primary research interest is drug discovery and development. His academic focus is primarily on the management of genitourinary malignancies, with a focus on prostate and testicular cancer.
